Assessment of Artificial Intelligence Chatbot Responses to Common Patient Questions on Bone Sarcoma

The potential impacts of artificial intelligence (AI) chatbots on care for patients with bone sarcoma is poorly understood. Elucidating potential risks and benefits would allow surgeons to define appropriate roles for these tools in clinical care.

Eleven questions on bone sarcoma diagnosis, treatment, and recovery were inputted into three AI chatbots. Answers were assessed on a 5-point Likert scale for five clinical accuracy metrics: relevance to the question, balance and lack of bias, basis on established data, factual accuracy, and completeness in scope. Responses were quantitatively assessed for empathy and readability. The Patient Education Materials Assessment Tool (PEMAT) was assessed for understandability and actionability.

Chatbots scored highly on relevance (4.24) and balance/lack of bias (4.09) but lower on basing responses on established data (3.77), completeness (3.68), and factual accuracy (3.66). Responses generally scored well on understandability (84.30%), while actionability scores were low for questions on treatment (64.58%) and recovery (60.64%). GPT-4 exhibited the highest empathy (4.12). Readability scores averaged between 10.28 for diagnosis questions to 11.65 for recovery questions.

While AI chatbots are promising tools, current limitations in factual accuracy and completeness, as well as concerns of inaccessibility to populations with lower health literacy, may significantly limit their clinical utility.